Early trial of BDB018 combo for tough cancers wraps up with just one patient

NCT ID NCT04840394

Completed Disease control Sponsor: Eikon Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BDB018 (immunotherapy drug) and pembrolizumab
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 1 participant, so it is too small to draw any conclusions about effectiveness. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR, SOLID

Contacts and locations

Locations

Florida Cancer Specialists

Sarasota, Florida, 34230, United States
START

San Antonio, Texas, 78229, United States
START MidWest

Grand Rapids, Michigan, 49501, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.